as 03-12-2025 3:44pm EST
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
Upcoming Earnings Alert:
Get ready for potential market movements as Talphera Inc. TLPH prepares to release earnings report on 18 Mar 2025.
Founded: | 2005 | Country: | United States |
Employees: | N/A | City: | SAN MATEO |
Market Cap: | 9.6M | IPO Year: | 2011 |
Target Price: | $4.50 | AVG Volume (30 days): | 48.2K |
Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.66 | EPS Growth: | N/A |
52 Week Low/High: | $0.50 - $1.27 | Next Earning Date: | 03-18-2025 |
Revenue: | $281,000 | Revenue Growth: | -24.05% |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
TLPH Breaking Stock News: Dive into TLPH Ticker-Specific Updates for Smart Investing
PR Newswire
2 months ago
PR Newswire
4 months ago
Simply Wall St.
4 months ago
GuruFocus.com
4 months ago
PR Newswire
4 months ago
PR Newswire
4 months ago
PR Newswire
5 months ago
PR Newswire
6 months ago
The information presented on this page, "TLPH Talphera Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.